Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
MP Patricelli, MR Janes, LS Li, R Hansen, U Peters… - Cancer discovery, 2016 - AACR
KRAS gain-of-function mutations occur in approximately 30% of all human cancers. Despite
more than 30 years of KRAS-focused research and development efforts, no targeted therapy …
more than 30 years of KRAS-focused research and development efforts, no targeted therapy …
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
MP Patricelli, MR Janes, LS Li, R Hansen, U Peters… - Cancer …, 2016 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> KRAS gain-of-function mutations occur in
approximately 30% of all human cancers. Despite more than 30 years of KRAS-focused …
approximately 30% of all human cancers. Despite more than 30 years of KRAS-focused …
[PDF][PDF] Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
MP Patricelli, MR Janes, LS Li, R Hansen, U Peters… - 2016 - scholar.archive.org
ABSTRACT KRAS gain-of-function mutations occur in approximately 30% of all human
cancers. Despite more than 30 years of KRAS-focused research and development efforts, no …
cancers. Despite more than 30 years of KRAS-focused research and development efforts, no …
[PDF][PDF] Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
MP Patricelli, MR Janes, LS Li, R Hansen, U Peters… - 2016 - academia.edu
ABSTRACT KRAS gain-of-function mutations occur in approximately 30% of all human
cancers. Despite more than 30 years of KRAS-focused research and development efforts, no …
cancers. Despite more than 30 years of KRAS-focused research and development efforts, no …
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
MP Patricelli, MR Janes, LS Li, R Hansen… - Cancer …, 2016 - pubmed.ncbi.nlm.nih.gov
KRAS gain-of-function mutations occur in approximately 30% of all human cancers. Despite
more than 30 years of KRAS-focused research and development efforts, no targeted therapy …
more than 30 years of KRAS-focused research and development efforts, no targeted therapy …
[PDF][PDF] Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
MP Patricelli, MR Janes, LS Li, R Hansen, U Peters… - 2016 - pdfs.semanticscholar.org
ABSTRACT KRAS gain-of-function mutations occur in approximately 30% of all human
cancers. Despite more than 30 years of KRAS-focused research and development efforts, no …
cancers. Despite more than 30 years of KRAS-focused research and development efforts, no …
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
MP Patricelli, MR Janes, LS Li, R Hansen… - Cancer …, 2016 - europepmc.org
A comment on this article appears in" Signalling: Putting the brakes on KRAS-G12C
nucleotide cycling." Nat Rev Cancer. 2016 Mar; 16 (3): 127. A comment on this article …
nucleotide cycling." Nat Rev Cancer. 2016 Mar; 16 (3): 127. A comment on this article …